Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog

Reference

• ADUSUMALLI, V. E., YANG, J. T., WONG, K. K., KUCHARCZYK, N. and SOFIA, R. D., 1991, Felbamate pharmacokinetics in the rat, rabbit and dog. Drug Metabolism and Disposition, 19, 1116–1125.
   PubMed Web of Science ®Google Scholar
• ALT, B. and KAUR, S., 1983a, Mammalian tissue acetylsalicylic acid esterases: identification, distribution and discrimination from other esterases. Journal of Pharmacology and Experimental Therapeutics, 226, 589–594.
   PubMed Web of Science ®Google Scholar
• ALT, B. and KAUR, S., 1983b, The effects of phenobarbital, 3-metrhylcholanthrene and benzo(a)pyrene on the hydrolysis of xenobiotics in the rats. Biochemical Pharmacology, 32, 3479–3480.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H. and RONFELD, R., 1983, Interspecies pharmacokinetic scaling and the Dedrick's plot. American Journal of Physiology, 245, R768—R775.
   Google Scholar
• DOHENY, H. C., RATNARAJ, N., WHITTINGTON, M. A., JEFFERYS, J. G. R. and PATSALOS, P. N., 1999, Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Research, 34, 161–168.
   Google Scholar
• DOHENY, M. H., ALAVIJEH, M. S., RATNARAJ, N. and PATSALOS, P. N., 1994, Piracetam kinetics in blood and cerebrospinal fluid. Epilepsia, 35, 85.
   Google Scholar
• EFTHYMIOPOULOS, C., BATTAGLIA, R. and STROLIN BENEDETTI, M., 1991, Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. Journal of Antimicrobial Chemotherapy, 27, 517–526.
   PubMed Web of Science ®Google Scholar
• GOBERT, J., 1975, Le piracétam: pharmacocinétique et biochimie. Paper presented at the Symposium Nootropil, UCB S. A. Brussels, 10 October, Bucarest, Romania, pp. 1–6.
   Google Scholar
• GONZALEZ, M. A., TOZER, T. N. and CHANG, D. T. T., 1975, Nonlinear tissue disposition: salicylic acid in rat brain. Journal of Pharmaceutical Sciences, 64, 99–103.
   PubMed Web of Science ®Google Scholar
• GOWER, A. J., HIRSCH, E., BOEHRER, A., NOYER, M. and MAREscAux, C., 1995, Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research, 22, 207–213.
   PubMed Web of Science ®Google Scholar
• GOWER, A. J., NOYER, M., VERLOES, R., GOBERT, J. and WÜLFERT, E., 1992, ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. European Journal of Pharmacology, 222, 193–203.
   Google Scholar
• KLITGAARD, H., MATAGNE, A., GOBERT, J. and WÜLFERT, E., 1998, Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology, 353, 191–206.
   Google Scholar
• LAPKA, R., REJHOLEC, V. and SmouR, S., 1990, Pharmacokinetics of piracetam in plasma and brain. Activas Nervosas Superior, 32, 58–59.
   PubMed Web of Science ®Google Scholar
• LöSCHER, W. and HoNACK, D., 1993, Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology, 232, 147–158.
   PubMed Web of Science ®Google Scholar
• LöSCHER, W., HöNACK, D. and RUNDFELDT, C., 1998, Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics, 284, 474–479.
   PubMed Web of Science ®Google Scholar
• LUKYANETZ, E. A., SHKRYL, V. M. and KOSTYUK, P. G., 2002, Selective blockade of N-type calcium channels by levetiractam. Epilepsia, 43, 9–18.
   PubMed Web of Science ®Google Scholar
• MARGINEANU, D. G. and KLITGAARD, H., 2002, Levetiracetam: mechanisms of action. In R. H. Levy, R. H. Mattson, B. S. Meldrum and E. Puracca (eds), Antiepileptic drugs, 5th edn (Philadelphia: Lippincott, Williams & Wilkins), pp. 419–427.
   Google Scholar
• MORGAN, E. W., YAN, B., GREENWAY, D., PETERSEN, D. R. and PARKINSON, A., 1994, Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). Archives of Biochemistry and Biophysics, 315, 495–512.
   PubMed Web of Science ®Google Scholar
• NICOLAS, J. M., COLLART, P., GERIN, B., MATHER, G., TRAGER, W., LEVY, R. and ROBA, J., 1999, Levetiracetam: in vitro metabolism assays and prediction of drug—drug interaction. In A. R. Boobis, P. Kremers, 0. Pelkonen and K. Pithan (eds), Proceedings of the European Symposium on the Prediction of Drug Metabolism in Man: Progress and Problems, 19–20 May, Liege, Belgium. Cost B1 EUR 18569 EN, Luxembourg: Office for Official Publications of the European Communities, pp. 193–195.
   Google Scholar
• NIESPODZIANY, I., KLITGAARD, H. and MARGINEANU, D. G., 2001, Levetiracetam inhibits the high-voltage-activated Ca2± current in pyramidal neurons of rat hippocampal slices. Neuroscience Letters, 306, 5–8.
   PubMed Web of Science ®Google Scholar
• NOUSIAINEN, U. and HANNINEN, 0., 1981, On the inducibility of cystolic and microsomal carboxyesterase by phenobarbital in rat tissues [Letter to the Editor]. Acta Pharmacologica et Toxicologica, 49, 77–80.
   Google Scholar
• NOYER, M., GILLARD, M., MATAGNE, A., HENICHART, J. P. and W0FLERT, E., 1995, The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European Journal of Pharmacology, 286, 137–146.
   Google Scholar
• OSTROWSKI VON, J., KEIL, M. and SCHRAVEN, E., 1975, Autoradiographische Untersuchungen zur Verteilung von Piracetam-14C bei Ratte und Hund. Arzneimittel-ForschunglDrug Research, 25, 589–596.
   PubMedGoogle Scholar
• RIGO, J. M., HANS, G., NGUYEN, L., ROCHER, V., BELACHEW, S., MALGRANGE, B., LEPRINCE, P., MOONEN, G., SELAK, I., MATAGNE, A. and KLITGAARD, H., 2002, The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology, 136, 659–672.
   PubMed Web of Science ®Google Scholar
• SCHWARK, W. S. and ECOBICHON, D. J., 1968, Subcellular localization and drug-induced changes of rat liver and kidney esterases. Canadian Journal of Physiology and Pharmacology, 46, 207–212.
   PubMed Web of Science ®Google Scholar
• STROLIN BENEDETTI, M., WHOMSLEY, R., NICOLAS, J. M., YOUNG, C. and BALTES, E., 2003, Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. European Journal of Clinical Pharmacology, 59, 621–630.
   PubMed Web of Science ®Google Scholar
• TACCONI, M. T. and WURTMAN, R. J., 1984, Physiological disposition of oral piracetam in Sprague—Dawley rats. Journal of Pharmaceutics and Pharmacology, 36, 659–662.
   PubMed Web of Science ®Google Scholar